[
  {
    "ts": null,
    "headline": "How To Build A $100,000 Dividend Portfolio That Could Yield 10.75% In 15 Years",
    "summary": "The Dividend Income Accelerator Portfolio targets income growth and diversification across sectors and countries. Learn why it offers strong returns and low risk.",
    "url": "https://finnhub.io/api/news?id=4bba80b64fd9b458cfb1fb516aebcdd2ca8aadeff95b4f1fe8fcb22ac8432e60",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748275200,
      "headline": "How To Build A $100,000 Dividend Portfolio That Could Yield 10.75% In 15 Years",
      "id": 134702503,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1036558944/image_1036558944.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The Dividend Income Accelerator Portfolio targets income growth and diversification across sectors and countries. Learn why it offers strong returns and low risk.",
      "url": "https://finnhub.io/api/news?id=4bba80b64fd9b458cfb1fb516aebcdd2ca8aadeff95b4f1fe8fcb22ac8432e60"
    }
  },
  {
    "ts": null,
    "headline": "Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer",
    "summary": "RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.",
    "url": "https://finnhub.io/api/news?id=adf207ec1a3aaaf04bea17f7a0640e99e0c94f8a1239286e0dee1a604041eaea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748266680,
      "headline": "Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer",
      "id": 134716330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.",
      "url": "https://finnhub.io/api/news?id=adf207ec1a3aaaf04bea17f7a0640e99e0c94f8a1239286e0dee1a604041eaea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer : First Quarter 2025 Transcript",
    "summary": "‌REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Q1 2025 Pfizer Inc Earnings Call EVENT DATE/TIME: APRIL 29, 2025 / 2:00PM GMT ...",
    "url": "https://finnhub.io/api/news?id=bbe3928141632a8ba128420d59e30886f970b4d313f77b0355fdeb516c23ff53",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748266324,
      "headline": "Pfizer : First Quarter 2025 Transcript",
      "id": 134701391,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "‌REFINITIV STREETEVENTS EDITED TRANSCRIPT PFE.N - Q1 2025 Pfizer Inc Earnings Call EVENT DATE/TIME: APRIL 29, 2025 / 2:00PM GMT ...",
      "url": "https://finnhub.io/api/news?id=bbe3928141632a8ba128420d59e30886f970b4d313f77b0355fdeb516c23ff53"
    }
  },
  {
    "ts": null,
    "headline": "Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates",
    "summary": "Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates",
    "url": "https://finnhub.io/api/news?id=f6e5ec550754e74e1cec1d8470e54027f79bc58af964ff9fc10bb0e842230b53",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748221664,
      "headline": "Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates",
      "id": 134697577,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f6e5ec550754e74e1cec1d8470e54027f79bc58af964ff9fc10bb0e842230b53"
    }
  },
  {
    "ts": null,
    "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
    "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
    "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748218034,
      "headline": "Is Novo Nordisk Immune To President Trump's Drug Price Plans",
      "id": 134697300,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453973904/image_1453973904.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Novo Nordisk's stock surged despite CEO changes, driven by GLP-1 success, record sales, and a $2.2B deal to combat obesity.",
      "url": "https://finnhub.io/api/news?id=58764c7eb5c1f7c305fb5b3175bab417232eab2adfadc7b42fac43f6eea5bcce"
    }
  }
]